In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance
Science Advances · 2024
DOI: 10.1126/sciadv.adl4013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2024. Verfasst von Yuao Zhu und 24 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer Worldwide Research, Development & Medical, Pearl River, NY 10965, USA. Hauptthemen laut MEDLINE: SARS-CoV-2, Drug Resistance, Viral, Antiviral Agents, Mutation. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
To facilitate the detection and management of potential clinical antiviral resistance, in vitro selection of drug-resistant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) against the virus M pro inhibitor nirmatrelvir (Paxlovid active component) was conducted. Six M pro mutation patterns containing T304I alone or in combination with T21I, L50F, T135I, S144A, or A173V emerged, with A173V+T304I and T21I+S144A+T304I mutations showing >20-fold resistance each. Biochemical analyses indicated inhibition constant shifts aligned to antiviral results, with S144A and A173V each markedly reducing nirmatrelvir inhibition and M pro activity. SARS-CoV-2 surveillance revealed that in vitro resistance–associated mutations from our studies and those reported in the literature were rarely detected in the Global Initiative on Sharing All Influenza Data database. In the Paxlovid Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients trial, E166V was the only emergent resistance mutation, observed in three Paxlovid-treated patients, none of whom experienced COVID-19–related hospitalization or death.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pfizer Worldwide Research, Development & Medical, Pearl River, NY 10965, USA.
- Pfizer Worldwide Research, Development & Medical, Groton, CT 06340, USA.
- Pfizer Worldwide Research, Development & Medical, Cambridge MA 02139, USA.
- Pfizer Worldwide Research, Development & Medical, La Jolla, CA 92121, USA.
ORCID-Profile: Yuao Zhu, Irina Yurgelonis, Stephen Noell, Li Hao, Patricia McMonagle, Mary Lynn Baniecki, Samantha E Greasley, Jennifer A Nicki, RoseAnn Ferre, Laura J Byrnes, Timothy K Craig, Claire M Steppan, Paul Liberator, Holly D Soares, Charlotte M N Allerton, Rhonda D Cardin
Zitieren
APA
Zhu, Y., Yurgelonis, I., Noell, S., Yang, Q., Guan, S., Li, Z., Hao, L., Rothan, H., Rai, D. K., McMonagle, P., Baniecki, M. L., Greasley, S. E., Plotnikova, O., Lee, J., Nicki, J. A., Ferre, R., Byrnes, L. J., Liu, W., Craig, T. K., …, & Cardin, R. D. (2024). In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance. Science Advances. https://doi.org/10.1126/sciadv.adl4013
Vancouver
Zhu Y, Yurgelonis I, Noell S, Yang Q, Guan S, Li Z, et al. In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance. Science Advances. 2024. doi:10.1126/sciadv.adl4013
BibTeX
@article{Zhu2024,
author = {Zhu, Yuao and Yurgelonis, Irina and Noell, Stephen and Yang, Qingyi and Guan, Shunjie and Li, Zhenghui and Hao, Li and Rothan, Hussin and Rai, Devendra K and McMonagle, Patricia and Baniecki, Mary Lynn and Greasley, Samantha E and Plotnikova, Olga and Lee, Jonathan and Nicki, Jennifer A and Ferre, RoseAnn and Byrnes, Laura J and Liu, Wei and Craig, Timothy K and Steppan, Claire M and Liberator, Paul and Soares, Holly D and Allerton, Charlotte M N and Anderson, Annaliesa S and Cardin, Rhonda D},
title = {In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance},
journal = {Science Advances},
year = {2024},
doi = {10.1126/sciadv.adl4013}
}
EUVIMED